CL2019003263A1 - Inhibidores de quinasa y usos de los mismos. - Google Patents

Inhibidores de quinasa y usos de los mismos.

Info

Publication number
CL2019003263A1
CL2019003263A1 CL2019003263A CL2019003263A CL2019003263A1 CL 2019003263 A1 CL2019003263 A1 CL 2019003263A1 CL 2019003263 A CL2019003263 A CL 2019003263A CL 2019003263 A CL2019003263 A CL 2019003263A CL 2019003263 A1 CL2019003263 A1 CL 2019003263A1
Authority
CL
Chile
Prior art keywords
kinase inhibitors
intermediaries
procedures
compositions
compounds
Prior art date
Application number
CL2019003263A
Other languages
English (en)
Inventor
Vicente Fidalgo Javier De
Anthony A Estrada
Jianwen A Feng
Brian Fox
Cinzia Maria Francini
Christopher R H Hale
Cheng Hu
Colin Philip Leslie
Maksim Osipov
Elena Serra
Zachary K Sweeney
Arun Thottumkara
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of CL2019003263A1 publication Critical patent/CL2019003263A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/04—Seven-membered rings having the hetero atoms in positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA PRESENTE DESCRIPCIÓN SE REFIERE GENERALMENTE A COMPUESTOS Y COMPOSICIONES, INTERMEDIARIOS, PROCEDIMIENTOS PARA SU PREPARACIÓN, Y SU USO COMO INHIBIDORES DE QUINASA.
CL2019003263A 2017-05-17 2019-11-14 Inhibidores de quinasa y usos de los mismos. CL2019003263A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762507698P 2017-05-17 2017-05-17
US201862664895P 2018-04-30 2018-04-30

Publications (1)

Publication Number Publication Date
CL2019003263A1 true CL2019003263A1 (es) 2020-04-17

Family

ID=64274744

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003263A CL2019003263A1 (es) 2017-05-17 2019-11-14 Inhibidores de quinasa y usos de los mismos.

Country Status (20)

Country Link
US (2) US11203600B2 (es)
EP (1) EP3624797A4 (es)
JP (2) JP7064512B2 (es)
KR (1) KR102638151B1 (es)
CN (1) CN110913858A (es)
AU (1) AU2018269743B2 (es)
BR (1) BR112019023918A2 (es)
CA (1) CA3063934A1 (es)
CL (1) CL2019003263A1 (es)
CO (1) CO2019012957A2 (es)
CR (1) CR20190566A (es)
DO (1) DOP2019000290A (es)
EC (1) ECSP19089214A (es)
IL (1) IL270648B2 (es)
MX (2) MX2019013645A (es)
PE (1) PE20200729A1 (es)
PH (1) PH12019550235A1 (es)
SG (1) SG10201913927VA (es)
TW (1) TWI794232B (es)
WO (1) WO2018213632A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3116729A1 (en) * 2018-10-19 2020-04-23 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with nad+ or a nad+ precursor
WO2021187605A1 (ja) * 2020-03-19 2021-09-23 田辺三菱製薬株式会社 含窒素複素環αシアノカルボニル化合物
TW202214617A (zh) 2020-06-02 2022-04-16 法商賽諾菲公司 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途
KR200493347Y1 (ko) 2020-07-06 2021-03-17 박혜진 휴대가 용이한 마스크
AU2022222458A1 (en) * 2021-02-19 2023-08-24 Kalvista Pharmaceuticals Limited Factor xiia inhibitors
US11897876B2 (en) 2021-11-11 2024-02-13 Genzyme Corporation Isoxazolidines as RIPK1 inhibitors and use thereof
WO2024025817A1 (en) * 2022-07-25 2024-02-01 Denali Therapeutics Inc. Solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5- dihydro-2h-pyrido[3,4-f][l,4]oxazepine-9-carbonitrile
WO2024044151A1 (en) * 2022-08-23 2024-02-29 Genzyme Corporation Methods for treating receptor-interacting protein kinase 1-mediated diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3861187B2 (ja) * 1996-08-02 2006-12-20 住友精化株式会社 チアゼピン誘導体の製造方法
SK3632003A3 (en) * 2000-09-27 2003-09-11 Ajinomoto Kk Benzodiazepine derivatives, pharmaceutical composition comprising same and their use
RU2456287C1 (ru) * 2011-05-20 2012-07-20 Николай Филиппович Савчук Стимуляторы секреции инкретиновых гормонов, способы их получения и применения
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
TWI637951B (zh) * 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
CN104059068B (zh) * 2013-03-20 2017-02-08 中国科学院上海药物研究所 β‑氨基羰基类化合物、其制备方法、药物组合物及其用途
AU2016215432B2 (en) * 2015-02-02 2020-07-30 Valo Early Discovery, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
UY36680A (es) * 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
PL3307739T3 (pl) * 2015-06-15 2021-05-31 Glaxosmithkline Intellectual Property Development Limited Regulatory nrf2

Also Published As

Publication number Publication date
US20200087319A1 (en) 2020-03-19
PH12019550235A1 (en) 2020-07-20
CR20190566A (es) 2020-06-14
CA3063934A1 (en) 2018-11-22
DOP2019000290A (es) 2020-03-15
JP2021193116A (ja) 2021-12-23
EP3624797A1 (en) 2020-03-25
JP7064512B2 (ja) 2022-05-10
IL270648B1 (en) 2023-11-01
CN110913858A (zh) 2020-03-24
TWI794232B (zh) 2023-03-01
ECSP19089214A (es) 2020-05-29
AU2018269743B2 (en) 2024-01-11
US11203600B2 (en) 2021-12-21
MX2022010755A (es) 2022-09-23
BR112019023918A2 (pt) 2020-06-02
CO2019012957A2 (es) 2020-05-29
JP2020520924A (ja) 2020-07-16
EP3624797A4 (en) 2021-07-21
IL270648B2 (en) 2024-03-01
AU2018269743A1 (en) 2020-01-16
KR102638151B1 (ko) 2024-02-16
PE20200729A1 (es) 2020-07-23
JP7241825B2 (ja) 2023-03-17
KR20200006125A (ko) 2020-01-17
TW201900618A (zh) 2019-01-01
MX2019013645A (es) 2020-09-17
SG10201913927VA (en) 2020-03-30
WO2018213632A1 (en) 2018-11-22
IL270648A (es) 2020-01-30
US20220041620A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
CL2019003263A1 (es) Inhibidores de quinasa y usos de los mismos.
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CO2018005369A2 (es) Inhibidores triazol de acc y usos de los mismos
UY38070A (es) Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer
NI201800128A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
DOP2018000147A (es) Compuestos inhibidores de la quinasa de unión a tank
CO2018005368A2 (es) Inhibidores pirazol de acc y usos de los mismos
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
CR20150524A (es) Compuestos de heteroarilo y sus usos
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
UY37015A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
CO2019006673A2 (es) Polimorfos
CO2019006687A2 (es) Polimorfos
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
BR112016018654A2 (pt) Composições de silicato estabilizadas e seu uso como composições antiperspirantes
UY37016A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
CO2020007044A2 (es) Derivados de pirrol como inhibidores de acc
CR20160224A (es) Composición herbicida que comprende inhibidores ACC
UY35876A (es) Derivados de pirazolopirimidin-2-ilo como inhibidores de jak
NI202000042A (es) Polimorfos
CO2019011271A2 (es) Análogos de deutetrabenazina, su preparación y uso
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
ECSP17063489A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos